Shares of Johnson & Johnson (NYSE:JNJ – Get Free Report) hit a new 52-week high during trading on Wednesday after UBS Group raised their price target on the stock from $280.00 to $320.00. UBS Group currently has a buy rating on the stock. Johnson & Johnson traded as high as $281.07 and last traded at $278.8010, with a volume of 1322509 shares. The stock had previously closed at $271.19.
Several other equities research analysts have also recently issued reports on the stock. Bank of America raised their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. HSBC set a $290.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Monday, July 6th. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research note on Wednesday, July 15th. Scotiabank reiterated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $272.83.
Read Our Latest Research Report on JNJ
Insider Activity
Key Stories Impacting Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: UBS raises price target and rating: UBS lifted its price target for Johnson & Johnson from $280 to $320 and upgraded the stock to “Buy.” The new target implies approximately 15.1% upside from the referenced price, providing the clearest positive catalyst for the move.
- Positive Sentiment: New products are replacing lost sales: Recent analysis says J&J replaced about $913 million in lost revenue with approximately $2.4 billion in new sales. This supports the company’s ability to offset product erosion and maintain growth, although the analysis notes that less than half of the new sales translated into retained value or earnings. Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones
- Neutral Sentiment: Upcoming earnings event: J&J will hold its third-quarter results conference call on October 13, giving investors a future catalyst to assess sales growth, pharmaceutical performance and full-year guidance. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
- Neutral Sentiment: Dividend comparison: Commentary portrays Procter & Gamble’s dividend profile as more dependable than J&J’s growth story and raises questions about whether a potential corporate event could affect J&J’s long-running payout record. Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story
- Negative Sentiment: Talc litigation remains a risk: A recent report questions whether a talc verdict adds to J&J’s legal exposure, keeping settlement costs, liabilities and uncertainty over future litigation as potential overhangs. Does Johnson & Johnson Talc Verdict Add To Its Legal Risk?
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brown Lisle Cummings Inc. increased its stake in Johnson & Johnson by 2.1% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 14,036 shares of the company’s stock worth $3,565,000 after acquiring an additional 284 shares during the last quarter. Cornerstone Financial Management LLC boosted its position in shares of Johnson & Johnson by 4.5% during the 2nd quarter. Cornerstone Financial Management LLC now owns 2,755 shares of the company’s stock valued at $700,000 after acquiring an additional 119 shares during the last quarter. Tucker Asset Management LLC grew its holdings in shares of Johnson & Johnson by 173.4% in the second quarter. Tucker Asset Management LLC now owns 5,011 shares of the company’s stock valued at $1,273,000 after purchasing an additional 3,178 shares in the last quarter. Principia Wealth Advisory LLC grew its holdings in shares of Johnson & Johnson by 208.7% in the second quarter. Principia Wealth Advisory LLC now owns 815 shares of the company’s stock valued at $207,000 after purchasing an additional 551 shares in the last quarter. Finally, Brown Financial Advisors increased its position in Johnson & Johnson by 10.6% in the second quarter. Brown Financial Advisors now owns 7,216 shares of the company’s stock worth $1,833,000 after purchasing an additional 694 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.
Johnson & Johnson Trading Up 1.6%
The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $260.21 and its 200-day moving average is $244.39. The company has a market cap of $663.98 billion, a PE ratio of 31.93, a P/E/G ratio of 2.54 and a beta of 0.24.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 62.11%.
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- The Pentagon’s Grok Rollout Puts These 3 Stocks in Focus
- Copper Surges as Shifting Trade Policy and AI Demand Collide
- Ulta Beauty’s Earnings Beat Was Stronger Than the Stock’s Reaction
- Bancorp’s Fintech Comeback Gains Momentum
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
